Boston-based Myomo (NYSE:MYO) has announced the pricing of a $15 million underwritten common stock offering. The wearable exoskeleton company is releasing 3 million shares at $5 each. Buyers have a 30-day window to purchase up to an additional 450,000 shares […]
Myomo Sets $15 Million Stock Offering to Expand Workforce During Growth Phase Read More »
Smith+Nephew (NYSE:SNN) has confirmed that job roles will be phased out in Tennessee, in response to an inquiry from MassDevice today. “Our aim is to evolve into a more efficient and dynamic entity,” a representative conveyed via email. “While optimizing
Smith+Nephew Announces US Job Reductions Read More »
Field Medical announced it has secured the FDA breakthrough device designation for its FieldForce pulsed field ablation (PFA) system. Additionally, this technology has been accepted into the FDA’s Total Product Lifecycle Advisory Program (TAP), which promotes preliminary, consistent strategic interactions
FDA Recognizes Groundbreaking Pulsed Field Ablation Tech by Field Medical Read More »
Acutus Medical has opted for a strategic realignment, envisioning a significant workforce reduction of 70%. Dr. Shaden Marzouk, the chair of Acutus’ board, characterized this downsizing as “hard but necessary steps.” Despite these layoffs, the company is determined to meet
Acutus Medical Reduces Workforce to Focus on Medtronic Partnership Read More »
Eisai Co., Ltd. and Biogen Inc. have made an announcement regarding the approval from Mexico’s Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) for their humanized anti-soluble aggregated amyloid-beta (Aß) monoclonal antibody, “Leqembi” (lecanemab), designed for early Alzheimer’s disease
Mexican Authorities Grant Approval for Leqembi as an Early Alzheimer’s Disease Treatment Read More »
**Merus N.V., a company specializing in oncology and working on groundbreaking, comprehensive, multispecific antibodies (Biclonics and Triclonics), announced the FDA’s nod for Bizengri (zenocutuzumab-zbco).** This milestone marks the first approved therapy for adults with advanced unresectable or metastatic pancreatic adenocarcinoma
FDA Greenlights Merus’ Bizengri for Pancreatic and Lung Cancer Treatment Read More »
GSK plc, in collaboration with Medicines for Malaria Venture (MMV), has revealed that the World Health Organization (WHO) has granted prequalification status to tafenoquine, marking it as the first single-dose treatment aimed at preventing relapses of *Plasmodium vivax* (P. vivax)
GSK and MMV Unveil New Single-Dose Tafenoquine for P. vivax Malaria with WHO Recognition Read More »
AstraZeneca has announced that Iskra Reic will now serve as the executive vice president (EVP) for international divisions, overseeing the strategic direction and fostering sustainable development throughout regions including China, Asian and Eurasian markets, Middle East & Africa, Latin America,
Iskra Reic Takes on New Role as Executive Vice President, International for AstraZeneca Read More »
Eli Lilly and Company revealed the primary results of the SURMOUNT-5 Phase 3b open-label randomized clinical trial. In this study, Zepbound (tirzepatide) achieved a 47% greater relative weight loss than Wegovy (semaglutide). On average, participants using Zepbound experienced a 20.2%
The World Health Organization has endorsed the prequalification of the Xpert MTB/RIF Ultra, a molecular diagnostic test for tuberculosis. This marks the first TB test approved for both disease diagnosis and antibiotic susceptibility testing, adhering to WHO’s rigorous prequalification criteria.
WHO Approves Xpert MTB/RIF Ultra for Tuberculosis Diagnosis Read More »